IndraLab

Statements


| 20

reach
"Harbour et al. do not demonstrate that BAP1 re-expression is sufficient to suppress the metastatic potential of uveal melanomas; however, if it does as one would predict from this study, substrates critical in migration, anoikis, and colonization should be considered."

reach
"In melanoma, BAP1 deficiency significantly elevated anaerobic glycolysis levels, leading to more lactate production in tumor cells [11]."

reach
"We present a unique case of BAP1-inactivated melanoma with anaplastic lymphoma kinase (ALK) fusion arising in a pre-existing BAP1-inactivated nevus in a 47-year-old female patient who presented with a dome-shaped red papule on the superior crus of the right antihelix."

reach
"BRCA1-Associated Protein-1 Inactivated Melanoma Arising in a Pre-existing Nevus With ALK Fusion and Low Tumor Mutational Burden."

reach
"Individuals with pathogenic BAP1 variants face an elevated risk of diverse tumors, notably BAP1-inactivated melanocytic nevi/tumors, uveal melanoma, cutaneous melanoma, mesothelioma, renal cell carcinoma, and basal cell carcinoma."

reach
"The BAP1 gene is located on chromosome 3, and loss of BAP1 has been suggested to drive T cell infiltration and help develop an inflammatory microenvironment in uveal melanoma [ 15 ]."

reach
"Here we report the clinical features, histopathologic findings, and chromosomal copy number data of 19 BAP1-inactivated melanocytomas (BIMs) and compare their features to those of five BAP1-inactivated melanomas."

reach
"Although not fully diagnostic, a mitotic count of ≥3/mm 2 and ≥6 CNAs in the appropriate context is supportive of a diagnosis of BAP1-inactivated melanoma."

reach
"BAP1-Inactivated Melanoma Arising From BAP1-Inactivated Melanocytic Tumor in a Patient With BAP1 Germline Mutation: A Case Report and Review of the Literature."

reach
"The addition of BAP1 loss increased tumor proliferation and melanoma size."

reach
"BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas."

reach
"RAF1 fusions have been recently detected in cutaneous melanocytic neoplasms, including conventional melanoma, congenital nevus and BAP-1 inactivated tumors."

reach
"Cutaneous BAP1-inactivated melanocytic tumors, previously classified as atypical Spitz Nevi, may have a dermal mitotic activity that can resemble melanoma and on the other hand, atypical Spitz tumors are sometimes difficult to differentiate from BAP1-inactivated melanoma."

reach
"To the best of our knowledge, this is the first case of BAP1-inactivated melanoma with a documented TERT-p hot spot mutation manifesting as the first presentation of BAP1 tumor predisposition syndrome."

reach
"Germline mutations in BAP1 predispose carriers to the BAP1 tumor predisposition syndrome (BAP1-TPDS), characterized by BAP1-inactivated nevi (BINs), uveal melanoma, cutaneous melanoma, mesothelioma, renal cell carcinoma, and other tumors."

reach
"BINs are highly penetrant, present in up to 90% of mutation carriers, and typically present as multiple, skin colored or reddish-brown, dome-shaped melanocytic tumors (also or previously called BAP1-inactivlated melanocytic tumors, Wiesner nevi, BAPomas, nevoid melanoma-like melanocytic proliferations, BAP1 mutant Spitz nevi, and melanocytic BAP1-mutated atypical intradermal tumors)."

reach
"In human uveal melanoma and renal cell carcinoma, BAP1 loss leads to a dedifferentiated stem-like phenotype associated with aggressive cancer behavior and poor patient outcome (2, 3)."

reach
"Interestingly, loss of BAP1 expression was found to promote T cell infiltration in uveal melanoma [79]."

reach
"The most strongly associated malignancies include mesothelioma, uveal and cutaneous melanomas, BAP1-inactivated melanocytic tumours and renal cell carcinoma.15 17 Recently published practice guidelines supported an additional association for meningioma, but do not classify it as a core tumour in this syndrome."

reach
"BAP1-TPDS is associated with an increased risk of a specific skin lesion, BAP1-inactivated melanocytic tumour (BIMT) (34), cutaneous melanoma (CM) (34), renal cell carcinoma (RCC) (35), and basal cell carcinoma (BCC) (36)."